- Home
- WDI vs ABUS Comparison
WDI vs ABUS Comparison
Compare WDI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- ABUS
- Stock Information
- Founded
- WDI 2021
- ABUS 2005
- Country
- WDI United States
- ABUS United States
- Employees
- WDI N/A
- ABUS N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- ABUS Health Care
- Exchange
- WDI Nasdaq
- ABUS Nasdaq
- Market Cap
- WDI 775.8M
- ABUS 711.2M
- IPO Year
- WDI N/A
- ABUS N/A
- Fundamental
- Price
- WDI $15.22
- ABUS $4.47
- Analyst Decision
- WDI
- ABUS Strong Buy
- Analyst Count
- WDI 0
- ABUS 2
- Target Price
- WDI N/A
- ABUS $5.00
- AVG Volume (30 Days)
- WDI 192.6K
- ABUS 1.6M
- Earning Date
- WDI 01-01-0001
- ABUS 11-05-2025
- Dividend Yield
- WDI 11.80%
- ABUS N/A
- EPS Growth
- WDI N/A
- ABUS N/A
- EPS
- WDI 1.12
- ABUS N/A
- Revenue
- WDI N/A
- ABUS $15,416,000.00
- Revenue This Year
- WDI N/A
- ABUS $138.02
- Revenue Next Year
- WDI N/A
- ABUS N/A
- P/E Ratio
- WDI $12.82
- ABUS N/A
- Revenue Growth
- WDI N/A
- ABUS 53.23
- 52 Week Low
- WDI $12.16
- ABUS $2.71
- 52 Week High
- WDI $14.69
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- WDI 63.35
- ABUS 66.04
- Support Level
- WDI $15.10
- ABUS $4.01
- Resistance Level
- WDI $15.25
- ABUS $5.10
- Average True Range (ATR)
- WDI 0.09
- ABUS 0.26
- MACD
- WDI 0.02
- ABUS 0.07
- Stochastic Oscillator
- WDI 91.94
- ABUS 58.75
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.